At CCRS, patients with weak cornea can undergo this strengthening procedure to prevent vision loss. The FDA approved CXL in 2016 to treat conditions such as keratectasia, a weakened cornea following LASIK, and keratoconus, a naturally occurring unstable cornea.
During CXL, the cornea is illuminated with UV light after Riboflavin (Vitamin B) is applied. This process creates cross-linking bridges between the corneal fibers and strengthens the tissue. CXL can be done instead of corneal transplantation for a fraction of the cost at CCRS.